SHANDA ASSET MANAGEMENT HOLDINGS Ltd Makes New Investment in Moderna, Inc. $MRNA

Key Points

• SHANDA ASSET MANAGEMENT HOLDINGS Ltd has made a new investment by purchasing 1,000,000 shares of Moderna, valued at approximately $28.35 million, accounting for 1.7% of its investment portfolio.
• Over 75% of Moderna's stock is owned by institutional investors and hedge funds, indicating strong institutional confidence in the company.
• Analysts have varying ratings on Moderna, with an average rating of "Hold" and a price target of around $42.88, despite recent earnings showing a significant year-over-year revenue decline.

SHANDA ASSET MANAGEMENT HOLDINGS Ltd bought a new stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,000,000 shares of the company's stock, valued at approximately $28,350,000. Moderna comprises 1.7% of SHANDA ASSET MANAGEMENT HOLDINGS Ltd's investment portfolio, making the stock its 6th biggest position. SHANDA ASSET MANAGEMENT HOLDINGS Ltd owned about 0.26% of Moderna as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the company. S Bank Fund Management Ltd bought a new stake in Moderna in the 1st quarter valued at $25,000. SVB Wealth LLC acquired a new stake in shares of Moderna during the first quarter worth $28,000. Costello Asset Management INC bought a new stake in shares of Moderna in the first quarter valued at about $30,000. Vega Investment Solutions acquired a new position in shares of Moderna in the fourth quarter valued at about $45,000. Finally, Sentry Investment Management LLC bought a new position in Moderna during the first quarter worth about $31,000. 75.33% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on MRNA shares. William Blair reissued a "market perform" rating on shares of Moderna in a report on Monday, June 2nd. Bank of America dropped their price target on shares of Moderna from $26.00 to $25.00 and set an "underperform" rating for the company in a research report on Tuesday, July 22nd. Evercore ISI set a $32.00 price objective on Moderna in a report on Friday, August 1st. Barclays cut their price target on shares of Moderna from $40.00 to $31.00 and set an "equal weight" rating for the company in a report on Monday, August 4th. Finally, Cowen assumed coverage on Moderna in a research note on Sunday, July 13th. They issued a "hold" rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, sixteen have given a Hold rating and four have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $42.88.

Moderna Price Performance

NASDAQ:MRNA opened at $24.09 on Monday. Moderna, Inc. has a one year low of $23.15 and a one year high of $79.96. The company has a market cap of $9.37 billion, a PE ratio of -3.20 and a beta of 1.93. The firm's 50 day simple moving average is $29.09 and its 200 day simple moving average is $28.81.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.99) by $0.86. The firm had revenue of $142.00 million during the quarter, compared to the consensus estimate of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The company's revenue for the quarter was down 41.1% on a year-over-year basis. During the same quarter last year, the firm earned ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. Equities research analysts expect that Moderna, Inc. will post -9.61 EPS for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.